Feed / SNDX

Syndax Pharmaceuticals, Inc.

SNDX

Healthcare · 19.66 -0.5% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Syndax Pharmaceuticals, Inc.'s move is being confirmed by its market group.

SNDX accounts for 0.5% of the group's measured movement across 5.6 effective names. raw member direction is mixed; 7 of 12 session-normalized paths align to the upside. Capital-flow agreement is 16%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

Session-normalized 5m paths
Role in the moveFlat / inactive path#12 of 12 by movement share
Group movement share0.5%Absolute path energy—not portfolio weight
Relative path-0.10%flat
Effective breadth5.6 / 12balanced
Relative alignment7/12upside path · 1 counter-moving
Capital-flow agreement16%not yet clean
SEQUENCE READ

No material onset for SNDX could be timestamped inside the aligned 5-minute window.

EVIDENCE COVERAGE

10 of 16 members in Clinical Biopharmaceuticals are active. 0 of 7 disclosed connections are confirming.

What would change this read
  • At least 11 of 16 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as NBIX begins moving with the group.

Invalidation: The live read weakens if participation falls to 5 of 16 members or fewer.

Watch this read

Who this business touches

The relationships behind SNDX

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

ABBVAbbVie Inc.partnerApr 30, 2026 ▾

“Included in cost of product sales are royalties owed to AbbVie on Revuforj sales as part of the Vitae License Agreement.”

INCYIncyte CorporationpartnerApr 30, 2026 ▾

“We are leading the commercialization and further development of revumenib and working closely with our collaboration partner, Incyte, on the commercialization and further development of axatilimab.”

Depended on by

INCYIncyte CorporationpartnerApr 28, 2026 ▾

“In addition to establishing collaborative or license arrangements under which other parties license our drug candidates for development and commercialization or under which we study our drug candidates in combination with such parties’ compounds or biologics,…”

Filing peers

LNTHSTOKPSN

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 11 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

SNDX is currently a Participant in the organic co-movement group Clinical Biopharmaceuticals. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.